We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+30.73%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$989M
AUM Growth
-$405M
Cap. Flow
-$292M
Cap. Flow %
-29.53%
Top 10 Hldgs %
77.09%
Holding
40
New
5
Increased
2
Reduced
13
Closed
12

Top Buys

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$34.6M
2
DYAX
DYAX CORPORATION
DYAX
+$19.4M
3
AKBA icon
Akebia Therapeutics
AKBA
+$14.4M
4
SCYX icon
SCYNEXIS
SCYX
+$7.35M
5
IMMU
Immunomedics Inc
IMMU
+$3.67M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$59.6M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$44.4M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$35M
4
ARWR icon
Arrowhead Research
ARWR
+$30.6M
5
PTCT icon
PTC Therapeutics
PTCT
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 66.74%
2 Miscellaneous 33.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TENX icon
26
Tenax Therapeutics
TENX
$68.5M
$1.29M 0.13%
+10
New +$1.54M
NBIX icon
27
Neurocrine Biosciences
NBIX
$15.2B
$1.02M 0.1%
68,968
-1,100,116
-94% -$15.5M
ATHE
28
CALL
Alterity Therapeutics
ATHE
$63.7M
$227K 0.02%
1,667
– –
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.61B
– –
-250,000
Closed -$5.22M
GILD icon
30
PUT
Gilead Sciences
GILD
$181B
– –
-2,400,000
Closed -$170M
LITS
31
Lite Strategy Inc
LITS
$37.1M
– –
-20,417
Closed -$4.54M
MGNX icon
32
MacroGenics
MGNX
$257M
– –
-199,398
Closed -$5.55M
PRTA icon
33
Prothena Corp
PRTA
$428M
– –
-1,554,918
Closed -$59.6M
PTCT icon
34
PTC Therapeutics
PTCT
$5.48B
– –
-981,761
Closed -$25.7M
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-656,767
Closed -$12.5M
FLXN
36
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-450,000
Closed -$7.4M
TSRO
37
DELISTED
TESARO, Inc.
TSRO
– –
-700,000
Closed -$20.6M
DYAX
38
CALL
DELISTED
DYAX CORPORATION
DYAX
– –
-500,000
Closed -$4.49M
ITMN
39
DELISTED
INTERMUNE INC
ITMN
– –
-300,801
Closed -$10.1M
DSCI
40
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-1,339,039
Closed -$17M
1
2

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, RA Capital Management held 40 positions worth $989M, down 29% from $1.39B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

RA Capital Management withdrew a net $292M in Q2 2014, closing 12 positions and reducing 13 holdings. Its most notable exit was Prothena Corp, an estimated $59.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 64% a quarter earlier, followed by Miscellaneous.

Against the trend, RA Capital Management opened a new position in Aravive, Inc. Common Stock worth $50.1M.

  • RA Capital Management's largest Q2 2014 buy was Aravive, Inc. Common Stock: 200,500 shares worth $50.1M.
  • RA Capital Management added most to DYAX CORPORATION in Q2 2014, an estimated $19.4M increase.
  • RA Capital Management's biggest Q2 2014 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $44.4M.
  • RA Capital Management fully exited Prothena Corp in Q2 2014, selling an estimated $59.6M.
  • RA Capital Management's ten largest holdings make up 77% of its $989M portfolio in Q2 2014.
  • RA Capital Management opened 5 new positions and closed 12 in Q2 2014.
  • RA Capital Management's portfolio value fell 29% quarter-over-quarter to $989M.

Based on RA Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.